ArticleEpilepsia2025
Assessment of antiseizure medication adherence based on postmortem toxicology and claimed prescriptions in cases of sudden unexpected death in epilepsy.
Article in Epilepsia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SUDEP update 2026: recent advances in experimental and clinical research.Current opinion in neurology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIndividuals with epilepsy are at a higher risk of dying suddenly and without explanation, known as sudden unexpected death in epilepsy (SUDEP). Seizures are a risk factor for SUDEP, and nonadherence to antiseizure medication (ASM) increases this risk. We aimed to assess adherence to ASMs at the time of death among young SUDEP cases by comparing prescription claims with postmortem toxicology at an individual level.
methodsWe identified all forensically autopsied SUDEP cases by assessing autopsy reports, toxicology reports, and Danish health registries from a previously identified nationwide population of sudden unexplained deaths in Denmark. We included cases aged 1-35 and 36-49 years between 2000-2019 and 2007-2019, respectively. We assessed adherence to ASMs by examining discrepancies or consistencies between any register-based claimed prescriptions and postmortem toxicology findings, resulting in four possible outcomes: evidence of adherence, nonadherence, nontreatment or undertreatment, and nonprescribed medication.
resultsOf 477 sudden unexplained deaths, 84 (18%) were identified as SUDEP. Among the SUDEP cases, 73 (87%) claimed ASMs before death and 67 (80%) had ingested ASM according to postmortem findings. Evidence of nonadherence was found in 16 (19%) SUDEP cases, constituting 22% (n = 16/73) of SUDEP cases who claimed ASM before death. Adherence was observed in 53 SUDEP cases (63%), comprising 73% (n = 53/73) of SUDEP cases who claimed ASM before death. Nonadherent SUDEP cases tended toward a higher prevalence of psychiatric diseases when compared with the remaining SUDEP cases. SIGNIFICANCE: By uniquely matching register-based prescription data with postmortem toxicology findings, we ascertained that 73% of SUDEP cases adhered to their claimed ASM, underscoring the necessity for continued vigilance in seizure management. However, improving medication adherence may possess preventive potential for SUDEP, as 22% exhibited nonadherence to their claimed ASM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.